-
Mashup Score: 0Sympathetic Blockade for Pain Associated With Nonaxial Bone Lesions in Patients With Cancer: An Uncontrolled Cohort - 2 month(s) ago
Background: Cancer-related bone pain remains a prevalent and frequently incapacitating ailment. Although conventional approaches effectively alleviate pain in most individuals, a subset of patients may continue to experience intractable pain. Current recommendations for treating cancer-related bone pain include oral analgesics and multimodal adjuvants, radiation therapy, and, in selected cases, intrathecal therapy. Cancer-related bone pain is mediated by a proliferation of sensory and sympathetic fibers. Thus, we believe that this pain can be successfully managed with minimally invasive sympathetic blockade (SB). Methods: In a retrospective observational cohort, we reviewed patients who underwent single-shot SB for uncontrolled cancer-related bone pain despite receiving opiate analgesics and other interventions. We documented the Edmonton Symptom Assessment Scale (ESAS) ratings, the numeric rating scale (NRS) pain scores, and the morphine equivalent daily dose (MEDD) before and after S
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 9NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024 - 2 month(s) ago
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
This month's #NCCNGuidelines Insights address the changing #ovariancancer treatment landscape & summarize current recommended PARP inhibitor use in the @NCCN Guidelines for Ovarian/Fallopian Tube/Primary Peritoneal Cancers https://t.co/yjRh4cjPnw #gyncsm Earn free #CME #CNE #CPE https://t.co/L0CHWWpVlg
-
-
Mashup Score: 3Racial and Ethnic Disparities in the Time to Ovarian Cancer Surgery in Patients at an Integrated Health Care Delivery System - 2 month(s) ago
Background: Disparities in ovarian cancer survival for African American women are multifactorial. We evaluated racial and ethnic differences in time to ovarian cancer surgery in members of an integrated health care system. Patients and Methods: In this retrospective cohort study, we identified women diagnosed with invasive epithelial-type ovarian cancer between January 1, 2008, through December 31, 2014, at an integrated health care system in the United States. We extracted data on cancer-related variables and sociodemographic variables from the health care system’s cancer registry and electronic health records. We included patients who received ovarian cancer surgery without neoadjuvant chemotherapy. We defined time to surgery as the number of days between diagnostic imaging study and surgery. We used Cox proportional hazards regression to evaluate crude and adjusted association of race and ethnicity with time to surgery. Results: Of 872 patients included, 55.1% were non-Hispanic Whit
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Racial and Ethnic #Disparities in the Time to #OvarianCancer Surgery in Patients at an Integrated Health Care Delivery System: https://t.co/yLqqhm8PPX #CancerDisparities #HealthDisparities #HealthEquity https://t.co/rYB44VCIln
-
-
Mashup Score: 35Is it Time to Forget the 5-Fluorouracil Bolus? - 2 month(s) ago
“Is it Time to Forget the 5-Fluorouracil Bolus?” published on Oct 2024 by National Comprehensive Cancer Network.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @dr_yakupergun: Is it Time to Forget the 5-Fluorouracil Bolus? @JNCCN https://t.co/ZJ60TzcqWF https://t.co/8Avon2kdON
-
-
Mashup Score: 0Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study - 2 month(s) ago
Background: Mohs micrographic surgery (MMS) is a promising treatment modality for melanoma in situ (MIS). However, variations in surgical technique limit the generalizability of existing data and may impede future study of MMS in clinical trials. Methods: A modified Delphi method was selected to establish consensus on optimal MMS techniques for treating MIS in future clinical trials. The Delphi method was selected due to the limited current data, the wide range of techniques used in the field, and the intention to establish a standardized technique for future clinical trials. A literature review and interviews with experienced MMS surgeons were performed to identify dimensions of the MMS technique for MIS that (1) likely impacted costs or outcomes of the procedure, and (2) showed significant variability between surgeons. A total of 8 dimensions of technical variation were selected. The Delphi process consisted of 2 rounds of voting and commentary, during which 44 expert Mohs surgeons a
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Establishing Consensus for #Mohs Micrographic Surgical Techniques in the Treatment of #Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study: https://t.co/2ufvawnQhi @wesley_yu #skcsm https://t.co/1g4M03CfrF
-
-
Mashup Score: 14Systemic Therapy Options for Peritoneal Mesothelioma - 2 month(s) ago
Peritoneal mesothelioma is an uncommon malignancy affecting approximately 300 new patients annually in the United States. Due to its low incidence, prospective clinical trials specific to this disease are scant. Recommendations regarding systemic therapy are mostly extrapolated from clinical trials conducted among patients with pleural mesothelioma. At present, the recommended first-line systemic treatment options may include immunotherapy with nivolumab plus ipilimumab or chemotherapy with pemetrexed plus either cisplatin or carboplatin. For second-line treatment, the other previously unchosen first-line option can be used. Off-label bevacizumab may be considered in combination with chemotherapy among carefully selected patients. The benefit of third-line treatment or beyond is less clear. Nonetheless, a number of single-agent regimens show modest activity. Anecdotal reports of children or young adults with peritoneal mesothelioma harboring ALK rearrangement have suggested the efficac
Source: jnccn.orgCategories: General Medicine News, Hem/OncsTweet-
RT @Erman_Akkus: 📘Systemic Therapy Options for Peritoneal Mesothelioma @JNCCN 👉https://t.co/sKh1sBB7ij @NCCN @OncoAlert #cancer #Oncolog…
-
-
Mashup Score: 0Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity - 2 month(s) ago
Background: Although the need to reduce the impact of financial toxicity among patients with cancer is widely acknowledged, few interventions have been developed to address this issue. We tested a novel, multiphase, patient-centered financial navigation (FN) intervention at a large academic medical center. Methods: We developed a financial toxicity screening tool consisting of the Comprehensive Score for Financial Toxicity (COST) measure plus several additional items based on patient feedback. After systematizing the screening process, 50 patients from the North Carolina Basnight Cancer Hospital were enrolled in the FN intervention following a positive screen for financial distress (COST score <23). The FN intervention involved one-on-one consultations with a trained financial navigator and included an initial comprehensive intake appointment to determine patient eligibility for financial assistance and follow-up appointments to discuss paperwork and application(s) status. We assessed
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related #FinancialToxicity: https://t.co/VsCdvkErvA https://t.co/7jidY44EH9
-
-
Mashup Score: 0Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests - 2 month(s) ago
Background: Some genomic alterations in non–small cell lung cancer (NSCLC) are known to differ according to race, sex, or age. These studies have been limited in sample size and thus they cannot detect the differences precisely and comprehensively. Methods: Tissue-based comprehensive genomic profiling was performed on 75,362 patients with NSCLC from the United States during routine clinical care. Additionally, we examined data of a Japanese NSCLC cohort with 1,019 patients. In the US cohort, 296 genes were examined for pathogenic alterations. Predominant genetic ancestry was inferred using a SNP-based approach, and patients were categorized into European (EUR), African (AFR), East Asian (EAS), Admixed American (AMR), and South Asian (SAS) ancestry groups. Patients were additionally stratified by histologic type, age (<40/≥40 years, <75/≥75 years), and sex. The prevalence of high tumor mutational burden (TMB-High) and microsatellite instability status was also calculated. Results: Strat
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in #NSCLC: From the Real-World Data of Cancer #GenomicProfiling Tests: https://t.co/XfvcNSn7JY #LCSM #cagenome https://t.co/de3vsgrJz9
-
-
Mashup Score: 0Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis - 2 month(s) ago
Background: Triple-negative breast cancer (TNBC) is a highly heterogeneous disease. The CBCSG010 trial is a prospective and multicenter phase III clinical trial confirming that adding adjuvant capecitabine significantly improved the 5-year disease-free survival (DFS) rate in patients with TNBC by 5.9%. In this study, we attempted to identify the specific population that benefited from adjuvant therapy. Methods: In this retrospective exploratory analysis, we performed RNA sequencing of tumor tissues from patients with TNBC in the CBCSG010 clinical trial. A single-sample gene set enrichment analysis algorithm and survival analysis were performed to characterize the intrinsic molecular features of the TNBC microenvironment and assess the associations between immune-related gene expression levels or immune cell counts with capecitabine treatment efficacy. Additionally, we performed immunohistochemical staining of 2 markers, PD-L1 and CD8, and hematoxylin-eosin staining of stromal tumor–inf
Source: jnccn.orgCategories: General Medicine News, Oncologists1Tweet-
Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative #BreastCancer in the CBCSG010 Clinical Trial Biomarker Analysis: https://t.co/8Z9dWTMe6a #BCSM #TNBC https://t.co/2WT6h5bsl9
-
-
Mashup Score: 34Is it Time to Forget the 5-Fluorouracil Bolus? - 2 month(s) ago
“Is it Time to Forget the 5-Fluorouracil Bolus?” published on Oct 2024 by National Comprehensive Cancer Network.
Source: jnccn.orgCategories: General Medicine News, Partners & KOLsTweet-
RT @dr_yakupergun: Is it Time to Forget the 5-Fluorouracil Bolus? @JNCCN https://t.co/ZJ60TzcqWF https://t.co/8Avon2kdON
-
Sympathetic Blockade for Pain Associated With Nonaxial Bone Lesions in Patients With Cancer: An Uncontrolled Cohort, by @CroldanMD et al of @MDAndersonNews: https://t.co/7YMnRDMZ73 #CancerPain https://t.co/JVHsB3O6Ve